Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders

Patent metadata

Field	Value
Publication number	US-10342480-B2
Application number	US-201414776168-A
Country	US
Kind code	B2
Filing date	Mar 17, 2014
Priority date	Mar 15, 2013
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

Methods for screening for therapies against autism spectrum disorders and methods for determining whether a subject would be responsive to a therapy against an autism spectrum disorder are disclosed.

First claim

What is claimed is:

1. A method for screening for a therapy against an autism spectrum disorder, said method comprising:
a) administering a therapy to a subject;
b) measuring brain activity in said subject by magnetoencephalography after administering an audio stimulus to the subject and measuring the 50 ms response; and
c) comparing the delay in the 50 ms response in the subject compared to a baseline of the subject,
wherein a decrease in the delay in the 50 ms response in said subject compared to the baseline of the subject indicates that the therapy is effective against said autism spectrum disorder.

2. The method of claim 1 , further comprising determining the baseline of the subject by measuring brain activity in said subject by magnetoencephalography after administering an audio stimulus to the subject prior to the administration of the therapy.

3. The method of claim 1 , wherein said therapy is a compound.

4. The method of claim 3 , wherein said compound is a small molecule.

5. The method of claim 1 , wherein said therapy is a non-pharmacological intervention.

6. The method of claim 1 , wherein the measurement of the 50 ms response is collapsed across hemispheres.

7. A method for determining whether a subject would be responsive to a therapy against an autism spectrum disorder, said method comprising:
a) administering a therapy to a subject;
b) measuring brain activity in said subject by magnetoencephalography after administering an audio stimulus to the subject and measuring the 50 ms response; and
c) comparing the delay in the 50 ms response in the subject compared to a baseline of the subject,
wherein a decrease in the delay in the 50 ms response in said subject compared to the baseline of the subject indicates that said subject is responsive to the therapy.

8. The method of claim 7 , further comprising determining the baseline of the subject by measuring brain activity in said subject by magnetoencephalography after administering an audio stimulus to the subject prior to the administration of the therapy.

9. The method of claim 7 , wherein said therapy is a compound.

10. The method of claim 9 , wherein said compound is a small molecule.

11. The method of claim 10 , wherein said small molecule is arbaclofen.

12. The method of claim 7 , wherein said therapy is a non-pharmacological intervention.

13. The method of claim 7 , wherein said subject is determined to be acceptable for inclusion in a drug trial.

14. The method of claim 7 , wherein the measurement of the 50 ms response is collapsed across hemispheres.

Assignees

• Childrens Hospital Philadelphia

Inventors

• Roberts Timothy P L
• Edgar James Christopher

Classifications

• A61B5/4848 Primary

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title

• A61B5/4076 Primary

  Diagnosing or monitoring particular conditions of the nervous system · CPC title

• A61B5/04009

  Human Necessities · mapped topic

• A61B5/246

  using evoked responses · CPC title